Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the pharmacokinetic behavior of Suc-HSA
after consecutive daily intravenous (i.v.) doses. The secondary objectives are to evaluate
the safety and tolerability and the antiretroviral and immunological effects of consecutive
daily i.v. doses of Suc-HSA.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
International Antiviral Therapy Evaluation Center
Collaborators:
Sanquin Sanquin Plasma Products BV University Medical Center Groningen